Catherine Cusack
Known title: DirectorCIK: 0001838868
Catherine Cusack's purchase track record
Catherine Cusack has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/21/2025 | SBRA | $40K | +11.6% | +27.2% | +7.5% |
| 5/22/2024 | SBRA | $101K | +15.4% | +33.0% | +11.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 791 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 8,310 | $0 | 6/17/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 817 | $0 | 5/29/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 781 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 872 | $0 | 11/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 877 | $0 | 8/29/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 8,178 | $0 | 6/12/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 805 | $0 | 5/30/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 833 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Open Market | 1,500 | $24K | 2/24/2025 | View on chart |
| SBRA | ▲ Buy | Open Market | 1,000 | $16K | 2/21/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 727 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 783 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 9,480 | $0 | 6/13/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 708 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Open Market | 7,000 | $101K | 5/22/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 729 | $0 | 2/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 677 | $0 | 11/30/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 771 | $0 | 8/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 11,382 | $0 | 6/14/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 540 | $0 | 5/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 499 | $0 | 2/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 449 | $0 | 11/30/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 379 | $0 | 8/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 8,751 | $0 | 6/14/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 214 | $0 | 5/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 219 | $0 | 2/28/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 221 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 175 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.